---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-272891"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2024-12-09T23:59:59+00:00"
generated_at: "2026-05-29T05:45:57.649524+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vor Bio announces positive clinical data for trem-cel + Mylotarg in AML; FDA agrees on registrational trial design

## Summary
- Preliminary data shows median RFS not reached after 7.4 months follow-up in 15 AML patients treated with trem-cel + Mylotarg.
- Engraftment achieved in 100% of patients: neutrophil engraftment median 9.5 days, platelet recovery median 16 days.
- CD33 editing efficiency median 90% (range 71-94%); doses up to 2 mg/m2 without significant toxicity.
- FDA agreed on registrational trial design for trem-cel + Mylotarg, including study population, control arm, primary endpoint.

## SEC filing metadata
- accession: 0001193125-24-272891
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2024-12-09T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312524272891/0001193125-24-272891-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312524272891/d818014d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-272891
- JSON: https://secwatch.observer/filing/0001193125-24-272891.json
- Plain text: https://secwatch.observer/filing/0001193125-24-272891.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.